Adverum Biotechnologies Inc (NASDAQ:ADVM) recorded a decrease of 16.16% in short interest. It was announced in January by FINRA the 1.97 million short interest on ADVM. Previously was reported down change of 16.16% from 2.35 million shares. Adverum Biotechnologies Inc (NASDAQ:ADVM) has 1.63 million shares average volume. It’ll cost 1 days for ADVM to recover its former position.

ADVM is reaching $3.59 during the last trading session, after increased 1.99%.Currently Adverum Biotechnologies, Inc. is uptrending after 13.23% change in last January 12, 2018. ADVM has 108,574 shares volume. The stock outperformed the S&P 500 by 13.23%.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye.The firm is valued at $225.70 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema.Currently it has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.

For more Adverum Biotechnologies, Inc. (NASDAQ:ADVM) news announced recently go to:,,, or The titles are as follows: “34 Stocks Moving In Friday’s Pre-Market Session – Benzinga” announced on November 02, 2018, “Premarket analyst action – healthcare – Seeking Alpha” on August 30, 2018, “Adverum Biotechnologies Appoints Katherine Bock as Vice President, Investor Relations & Corporate Communications – GlobeNewswire” with a publish date: July 24, 2018, “Move Beyond Bargain Hunting: 5 Stocks With Rising P/E – Nasdaq” and the last “Premarket Gainers as of 9:05 am (03/05/2018) – Seeking Alpha” with publication date: March 05, 2018.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Analyst Ratings Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *